ArticleBMC research notes2021

Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer.

Shotaro Nakanishi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.